Navigation Links
GlycoMark®, Inc. Announces Partnership with Premier Medical Laboratory Services to Expand Diabetes Test Menu
Date:9/28/2018

GlycoMark®, Inc. has announced a partnership with Premier Medical Laboratory Services (PMLS) to increase the availability of the GlycoMark test, the only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions in patients with diabetes. With the partnership, PMLS will promote and offer the GlycoMark test to its network of physicians through its sales organization and MD DiabeticPro® laboratory services.

“As an industry leader, we strive to provide physicians with innovative solutions that enable the best possible care for patients,” said Melanie Stallings, Director of Laboratory Operations of Premier Medical Laboratory Services. “We believe that the GlycoMark test provides important additional information to help physicians personalize patient treatment plans and drive better clinical outcomes.”

Hyperglycemia, which leads to numerous diabetic vascular complications, isn’t always easily detected. Nearly 40% of patients who are deemed to be in “good control”, based on A1C glucose averages, may have significant postprandial hyperglycemia or glycemic variability. Furthermore, a periodic blood glucose is not always reliably timed or performed, and may yield inaccurate results.

“We are very pleased with our partnership with Premier Medical Laboratory. By adding the GlycoMark test to PMLS’s MD DiabeticPro menu, physicians will have increased awareness and access to the test to help improve the management of patients with diabetes,” said Hiro Ishibashi, President of GlycoMark, Inc.

ABOUT GLYCOMARK

GlycoMark, Inc., based in Manhattan, New York, is dedicated to improving the management and health of patients with diabetes. The company is a joint venture among Toyota Tsusho America, Inc. (New York, NY), Toyota Tsusho Corporation (Tokyo, Japan), and Nippon Kayaku Co., Ltd. (Tokyo, Japan), and is the exclusive supplier of the GlycoMark test in the U.S., Europe, Australia, Asian Pacific and the Middle East. The GlycoMark test is the only FDA cleared non-fasting blood test that detects hyperglycemia and hyperglycemic excursions occurring in the prior 1 to 2 weeks. Since its discovery, the GlycoMark Test, a quantitative test for 1,5-Anhydroglucitol (1,5-AG), has been described in more than 1,300 scientific and medical publications and is shown to be independently associated with complications of diabetes. More information is available at http://www.GlycoMark.com.

ABOUT PREMIER MEDICAL LABORATORY

Premier Medical is a highly complex, advanced diagnostic lab with multiple specialty programs and a full complement of chemistry, immunoassay and hematology testing, located in Greenville, SC. PMLS offers the following specialty tests, to provide clinicians with clinically relevant testing in order to improve patient outcomes and quality of life:

  • MD HeartPro – An advanced cardiovascular profile that identifies hidden risk factors not identified by common cardiovascular testing
  • MD AllergyPro – Serum based IgE testing
  • MD DrugPro – A Medication Compliance Monitoring toxicology program
  • MD WellnessPro – A comprehensive look at a patient’s wellness profile
  • MD GeneticPro – Premier Medical’s constantly growing molecular department’s menu includes Pharmacogenomics, Hereditary Cancer Panels, Women’s Health Vaginitis/Vaginosis/STI panel, Respiratory Pathogen Panel, Gastrointestinal Pathogen Panel and Hepatitis C Genotyping.

With our partnership with GlycoMark, we would like to announce our new test panel:

  • MD DiabeticPro : Glucose w eAG, Hemoglobin A1C, GlycoMark, Hemoblobin A1C/GlycoMark Ratio, Adiponectin

    Insulin and C-Peptide

GlycoMark is a registered trademark of GlycoMark, Inc. MD DiabeticPro is a registered trademark of Premier Medical Laboratory.

Read the full story at https://www.prweb.com/releases/glycomark_inc_announces_partnership_with_premier_medical_laboratory_services_to_expand_diabetes_test_menu/prweb15787536.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology technology :

1. DistinctBright, Probiotic Cleaner, Announces their Probiotic Cleaner is Safe for Pets
2. Annual Conference about Technology Solutions for People with Disabilities Announces Program
3. Probiotic Action Announces Probiotics Lead the Digestive Health Market
4. Verenium Announces Preliminary Financial Results For Fiscal 2012
5. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
6. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
7. EAG Announces New General Manager of Release-To-Production (RTP) Division
8. DuPont Tate & Lyle Bio Products Announces Novel Application for Zemea® Propanediol
9. Probiotic Action Announces China’s $5 Billion Dollar Investment in Probiotics
10. EAS Consulting Group, Experts in Quality Regulatory Services Related to FDA Issues, Announces Upcoming Dietary Supplement Seminars in Salt Lake City
11. 3D Biomatrix Announces Stipend to Present at Spring 2013 Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/3/2019)... ... October 02, 2019 , ... Rapid Novor, Inc., ... announce that it has moved into a new, 5000 sqft, purpose-built, state-of-the-art facility. ... facility demonstrates the company's continuous commitment to quality research and service offerings. ...
(Date:9/24/2019)... ... September 24, 2019 , ... ... technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer ... focused on the development of therapies to treat central nervous system (CNS) ...
(Date:9/17/2019)... ... 2019 , ... Catalent, a global leader in clinical supply ... Pacific (APAC) will present at the upcoming 3rd Annual Accelerating Clinical Trials in ... Thursday, Sept. 26, at 10:10 a.m., Ms. Delaney will present “Singapore: APAC’s Clinical ...
(Date:9/17/2019)... (PRWEB) , ... September 16, 2019 , ... ... Nationwide via CNBC on Saturday, September 21st @11:00am ET. Check local listings for ... Pte. Ltd. (Credo Biomedical), a molecular diagnostic company from Singapore dedicated to ...
Breaking Biology Technology:
(Date:10/4/2019)... , ... October 04, 2019 , ... ... will be held November 10 at the Grand Elysée Hamburg Rothenbaumchaussee in Hamburg. ... Europe again this November,” said Miao Guo, Vice President of Operations and spokesperson ...
(Date:10/3/2019)... ... October 01, 2019 , ... The ... of chemicals, reagents, and medias and to be a more environmentally sustainable evolution ... culmination of years of experience and feedback from the original version we launched ...
(Date:10/3/2019)... ... 02, 2019 , ... Connecticut Innovations (CI), Connecticut’s strategic venture ... innovative, growing companies, today announced that it has closed on a $750,000 investment ... the 2018 VentureClash competition. , The outlay is part of ...
Breaking Biology News(10 mins):